Novartis

Novartis Access and Government of Cameroon Sign Memorandum of Understanding to Fight Chronic Diseases

Novartis reaches agreement with Cameroon to supply medicines against chronic diseases for the poorest populations
Summary: 
  • Novartis reaches agreement with Cameroon to supply medicines against chronic diseases for the poorest populations
  • Cameroon Baptist Convention Health Services have started distributing medicines in selected parts of the country; capacity-building activities to kick off this month
  • Cameroon becomes the sixth country to launch Novartis Access
Press Release
  • Novartis reaches agreement with Cameroon to supply medicines against chronic diseases for the poorest populations
  • Cameroon Baptist Convention Health Services have started distributing medicines in selected parts of the country; capacity-building activities to kick off this month
  • Cameroon becomes the sixth country to launch Novartis Access

World Heart Day 2017 – a Global Vision for Healthy Hearts

On World Heart Day 2017, the Novartis Foundation and our partners are proud to report the ambitious steps we are taking around the world to tackle hypertension in low- and middle-income countries (LMICs).
Article

Cardiovascular diseases, including hypertension, account for nearly half of the world’s deaths from non-communicable diseases (NCDs).[1] With almost 75% of NCD deaths occurring in LMICs,[2] the Novartis Foundation recognizes the importance of World Heart Day in raising awareness of cardiovascular disease and promoting good heart health globally.

Novartis Foundation Announces IntraHealth and PATH As Latest Better Hearts Better Cities Partners in Dakar, Senegal

The Novartis Foundation is pleased to announce IntraHealth International and PATH as local implementation partners for the Better Hearts Better Cities initiative in Dakar, Senegal.
Article

The Novartis Foundation is pleased to announce IntraHealth International and PATH as local implementation partners for the Better Hearts Better Cities initiative in Dakar, Senegal.

Novartis Ranks Fourth in Fortune’s “Change the World” List and Moves up in Dow Jones Sustainability Index

Novartis has again been recognized for its commitment to doing well by doing good in key global rankings.
Press Release

September 11, 2017 /3BL Media/ - Novartis has again been recognized for its commitment to doing well by doing good in key global rankings.

Novartis and Medicines for Malaria Venture Launch Patient Trial in Africa for KAF156, a Novel Compound Against Multidrug-resistant Malaria

Press Release

  • Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission

  • KAF156 is first compound from the imidazolopiperazines, a novel class of antimalarials, to enter phase IIb combination studies

  • Clinical trial has started early August in adults with malaria and is planned to expand to adolescents and children in a total of nine countries in Africa and Asia

Malaria Fighter Rides Bicycle into Battle with Disease, Story from Novartis

As World Mosquito Day approaches, revisit this story from the Novartis archives about healthcare worker Dismus Mwalukwanda who’s on the front line in the battle against malaria in Zambia.
Article

Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority

Novartis Story About the Rising Concern of Malaria That Resists Treatment

As World Mosquito Day approaches, revisit this story from the Novartis archives on how the rising concern of resistance threatens the great progress made against malaria
Article

In Kenya, about three-quarters of the population is at risk for malaria, and all four species of the malaria parasite that infect humans occur in the country. Although there has been substantial progress, malaria remains the leading cause of mortality in Kenya, killing an estimated 30,000 people every year, most of them children under 5 years old.

Novartis Story Celebrates a Life Dedicated to Fighting Malaria

As World Mosquito Day approaches, revisit this story from the Novartis archives celebrating the hard work done by Agnes Akoth to fight against malaria in Kenya.
Article

In Kenya, about three-quarters of the population is at risk for malaria, and all four species of the malaria parasite that infect humans occur in the country. Although there has been substantial progress, malaria remains the leading cause of mortality in Kenya, killing an estimated 30,000 people every year, most of them children under 5 years old.

Watch: Healthcare Access Pioneer Doc Mae on Making a Difference for Children with Cancer

New short film by Sandoz, a Novartis Division, celebrates the work of Dr. “Doc” Mae Dolendo, a Pediatric Oncologist in the Philippines who has dedicated her life to treating children with cancer and finding ways to overcome healthcare access challenges
Multimedia with summary

Dr. “Doc” Mae Dolendo is a Pediatric Oncologist at the Southern Philippines Medical Center. She has dedicated her life to treating children with cancer and finding new ways to overcome the healthcare access challenges children, families and healthcare professionals face on the island of Mindanao. Doc Mae’s work is supported by World Child Cancer and Sandoz. Sandoz is proud to support healthcare access pioneers like Doc Mae.

Sandoz Expands Partnership with World Child Cancer, to Help Children Access Treatment in Four Developing Countries

Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana
Summary: 
  • Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana
  • In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low as 10%
  • Sandoz is committed to working with key stakeholders to pioneer novel ways of expanding access to healthcare
Press Release
  • Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana
  • In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low as 10%
  • Sandoz is committed to working with key stakeholders to pioneer novel ways of expanding access to healthcare

Pages

Subscribe to Novartis